U.S. Application No. 09/738,742 Attorney Docket No. C058

AMENDMENTS TO THE CLAIMS

1. (Previously presented) A compound having the formula (I):



(I)

and salts thereof;

wherein R is:



;

wherein X and X" are independently selected from C=O, C=S, C=NH, $C=NR^X$, S=O or SO_2;

wherein n is 1;

wherein R^X is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is $X"R^Y$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A is H, NH_2, NHR^A, NR^AR^B, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^A and R^B are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

provided that when B is H and X is C=O, then A is other than

(a) a pyridinyl ring substituted with a single $NHC(O)R^D$ substitutent or

(b) a (C_5-C_6) saturated cycloalkyl ring substituted with a single $NHC(O)R^D$ substitutent, wherein R^D is (C_1-C_{17}) unsubstituted alkyl or (C_2-C_{17}) unsubstituted alkenyl;

wherein R^1 is



;

wherein X' and X''' are independently selected from C=O, C=S, C=NH, $C=NR^{X'}$, S=O or SO_2;

wherein m is 0 or 1;

wherein $R^{X'}$ is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B' is $X'''R^{Y'}$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{Y'}$ is selected from hydrido, alkyl, alkenyl, alkynyl, aryl,

heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH_2, $NHR^{A'}$, $NR^{A'}R^{B'}$, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{A'}$ and $R^{B'}$ are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R^{50}-R^{53} is independently selected from C_1-C_{15} alkyl;

alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R^2 is



wherein K and K' together form a C_3-C_7 cycloalkyl or heterocyclyl ring or a C_5-C_{10} aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J, NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl,

alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,



and



;

wherein each of R^{24}, R^{25}, and R^{26} is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or

alternatively, wherein J, together with R^{17}, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or

alternatively, wherein J, together with both R^{17} and R^{18}, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R^{17} and R^{18} is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and



; or

wherein R^{17} and R^{18} taken together can form a group consisting of ketal, thioketal,



wherein each of R^{22} and R^{23} is independently selected from the group

consisting of hydrido and alkyl.

2. (Previously presented) A compound having the formula (I):



(I)

and salts thereof;

wherein R is:



;

wherein X and X" are independently selected from C=O, C=S, C=NH, $C=NR^X$, S=O or SO_2;

wherein n is 1;

wherein R^X is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is $X"R^Y$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl

or heterocyclyl; and

wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A is aryl;

provided that when B is H and X is C=O, then A is other than a phenyl ring substituted with either:

(a) –O-((C_8-C_{15}) unsubstituted alkyl), wherein said phenyl ring may be further optionally substituted with one substituent selected from halo, nitro, (C_1-C_3) alkyl, hydroxyl, (C_1-C_3) alkoxy or (C_1-C_3) alkylthio; or

(b) –NHC(O)R^D, wherein the phenyl ring may be further optionally substituted with 1-2 substituents independently selected from amino, nitro, (C_1-C_3) alkyl, hydroxyl, (C_1-C_3) alkoxy, halo, mercapto, (C_1-C_3) alkylthio, carbamyl or (C_1-C_3) alkylcarbamyl, wherein R^D is (C_1-C_{17}) unsubstituted alkyl or (C_2-C_{17}) unsubstituted alkenyl;

wherein R^1 is



;

wherein X' and X"' are independently selected from C=O, C=S, C=NH, C=N$R^{X'}$, S=O or SO_2;

wherein m is 0 or 1;

wherein $R^{X'}$ is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B' is X"'$R^{Y'}$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{Y'}$ is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH_2, $NHR^{A'}$, $NR^{A'}R^{B'}$, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{A'}$ and $R^{B'}$ are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R^{50}-R^{53} is independently selected from C_1-C_{15} alkyl;

alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R^2 is



wherein K and K' together form a C_3-C_7 cycloalkyl or heterocyclyl ring or a C_5-C_{10} aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J,

NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,



and



;

wherein each of R^{24}, R^{25}, and R^{26} is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or

alternatively, wherein J, together with R^{17}, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or

alternatively, wherein J, together with both R^{17} and R^{18}, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R^{17} and R^{18} is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and



; or

wherein R^{17} and R^{18} taken together can form a group consisting of ketal, thioketal,



wherein each of R^{22} and R^{23} is independently selected from the group consisting of hydrido and alkyl.

Claims 3-4 (Canceled)

5. (Previously presented) The compound according to claim 1, wherein R is selected from the group consisting of:


,

,

,

and

;

wherein each of R^3, R^4, R^5, and R^6 is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and wherein R^{200} is selected from the group consisting of hydrido, heterocyclyl, and heteroaryl.

6. (Previously presented) The compound according to claim 5, wherein R is selected from



;

and wherein $R^{4'}$ is selected from the group consisting of heteroaryl, and heterocyclyl.

7. (Previously presented) The compound according to claim 6, wherein R is



8. (Currently amended) The compound according to either of claims 1 or 2, wherein R^1 is selected from the group consisting of:





;

wherein R^8 is selected from a natural amino acid side chain or an amino acid side chain that is not naturally occurring;

wherein each of R^9, R^{10} and R^{11} is selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl;

wherein R^{12} is selected from the group ~~consisiting~~ consisting of heterocyclyl, heteroaryl, aryl, and alkyl and

wherein R^{13} is selected from (C_1-C_3-alkyl) and aryl.

9. (Currently amended) The compound according to claim 8, wherein R^1 is selected from the group consisting of:





and



;

wherein R^8 is selected from tryptophan side chain and lysine side chain;

wherein each of R^{10} and R^{11} is independently selected from hydrido and alkyl;

wherein R^{12} is selected from imidazolyl, N-methylimidazolyl, indolyl, quinolinyl, benzyloxybenzyl, and benzylpiperidenylbenzyl; and

wherein X^4 is ~~selected from~~ fluoro~~, and~~ or trifluoromethyl.

10. (Previously presented) The compound according to either of claims 1 or 2, wherein J is selected from the group consisting of hydrido, amino, azido and



;

wherein R^{17} and R^{18} taken together form a group selected from ketal,

 and 

;

or wherein R^{17} is hydroxyl when R^{18} is hydrido;

or wherein J, together with R^{17}, forms a heterocyclyl ring.

11. (Original) The compound according to claim 10, wherein R^2 is selected from the group consisting of



and



;

wherein R^{17} and R^{18} taken together form a group selected from


and

, wherein R^{22} is selected from the group consisting of H and alkyl; and wherein R^{19} is selected from the group consisting of hydrido, amino, azido and


12. (Original) The compound acccording to claim 11, wherein R^2 is



Claims 13-14 (Canceled)

15. (Previously presentcd) A pharmaceutical composition comprising the compound according to cither of claims 1 or 2 and a pharmaceutically acceptable carrier.

16. (Currently amended) A method of treating ~~or preventing~~ a bacterial infection in a subject, comprising the step of administering a therapeutically-effective amount of the pharmaceutical composition according to claim 15 to a subject in need thereof for a time and under conditions effective to control or eliminate said bacterial infection.

17. (Currently amended) The method according to claim 16, wherein said subject is selected from the group consisting of a human, an animal, a cell culture ~~or~~ and a plant.

18. (Original) The method according to claim 16, wherein said bacterial infection is caused by a gram-positive bacteria.

19. (Original) The method according to claim 18, wherein said bacteria is an antibiotic-resistant bacteria.

20. (Original) The method according to claim 19, wherein said antibiotic-resistant bacteria are resistant to an antibiotic selected from the group consisting of vancomycin, methicillin, glycopeptide antibiotics, penicillin and daptomycin.

21. (Original) The method according to claim 16, further comprising the step of co-administering more than one compound of Formula (I) to a subject in need thereof.

22. (Original) The method according to claim 16, further comprising the step of co-administering an antimicrobial agent other than a compound of Formula (I) to a subject in need thereof.

23. (Previously presented) The method according to claim 22, wherein said antimicrobial agent is selected from the group consisting of penicillins, carbapenems, cephalosporins, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin,

polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents, trimethoprim, pyrimethamine, synthetic antibacterials, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, everninomicin, glycopeptide, glycylcycline, ketolides, oxazolidinones, imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, Ziracin (56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-hexopyranosyl)flambamycin), LY333328 (oritavancin), Linczolid (N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide), Synercid (dalfopristin-quinupristin), Aztreonam (2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl] amino]-2-oxoethylidene]amino]oxy]-2-methyl-propanoic acid), Metronidazole (2-methyl-5-nitro-1H-imidazole-1-ethanol), Epiroprim (5-[[3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl]methyl]-2,4-pyrimidinediamine), OCA-983 (1-[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-2,5-anhydro-3-S-[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]-1,4-dideoxy-3-thio-D-threo-pentitol), GV-143253 (trinem), Sanfetrinem ((1S, 5S, 8aS, 8bR)-1, 2, 5, 6, 7, 8, 8a, 8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid), CS-834 ((4R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3R)-5-oxo-3-pyrrolidinyl]thio]-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), Biapenem (6-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6, 7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt), KA 159 (stipiamide), Dynemicin A ((1S,4R,4aR,14S,14aS,18Z)-1,4,7,12,13, 14-hexahydro-6,8,11-trihydroxy-3-methoxy-1-methyl-7,12-dioxo-4a,14a-epoxy-4,14-[3]hexene[1,5]diynonaphtho[2,3-c]phenanthridine-

2-carboxylic acid), DX8739 ((4R,5S,6S)-3-[[(3S,5S)-5-[[4-[(2S)-5-amino-2-hydroxy-1-oxopentyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), DU 6681 ((4R,5S,6S)-3-[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid), Cefluprenam ((2E)-N-(2-amino-2-oxoethyl)-3-[(6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoro methoxy)imino]acetyl] amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-N-ethyl-N-methyl-2-propen-1-aminium inner salt), ER 35786 ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrochloride), Cefoselis ((6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid), Sanfetrinem celexetil ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo- zeto[2,1-a]isoindole-4-carboxylic acid 1-[(cyclohexyloxy)carbonyl] oxy]ethyl ester), Cefpirome (1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl] amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-5H-cyclopenta[b]pyridinium inner salt), HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), RU-59863 (C-7 catechol substituted cephalosporin), KP 736 ((6R,7R)- 7-[[(2Z)-(2-amino-4-thiazolyl)[[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy] imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt), Rifalazil (1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-

rifamycin VIII), MEN 10700 ((5R,6S)-3-[[(2-amino-2-oxoethyl)methylamino]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), Lenapenem ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), BO 2502A ((4R,5S,6S)-3-[(2S,3'S,4S)-[2,3'-bipyrrolidin]-4-ylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), NE-1530 (3'-sialyllacto-N-neotetraose), PR 39 (L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolinamide [SEQ ID NO; 1]), K130 (5-[[4-[3-[[4-[(4-aminophenyl)sulfonyl]phenyl]amino]propoxy]-3,5-dimethoxyphenyl] methyl]-2,4-pyrimidinediamine), PD 138312 ((R)- 7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), PD 140248 (7-[(3R)-3-[(1S)-1-aminoethyl]-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), CP 111905 (5-deoxy-5-[[(2E)-3-[3-hydroxy-4-(2-propenyloxy)phenyl]-2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylene-D-neo-inositol), Sulopenem ((5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), ritipenam acoxyl ((5R,6R)-3-[[(aminocarbonyl)oxy]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (acetyloxy)methyl ester), RO-65-5788 ((6R,7R)- 7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-3-[(E)-[(3'R)-1'-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl]-8-oxo-5-thia-1-

azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt), Sch-40832 (N-[[48-[1-[[2,6-dideoxy-3-O-(2,6-dideoxy-D-arabino-hexopyranosyl)-D-arabino-hexopyranosyl]oxy]ethyl]-15-ethylidene-1,3a,4,5,10,11,12,13,14,15,19,20,21,22,28,29,41,42-octadecahydro-41-hydroxy-12,45-bis(1-hydroxyethyl)-1-(hydroxymethyl)-22-(1-hydroxy-1-methylpropyl)-36-methyl-51,54,57-tris(methylene)-3-(methylthio)-10,13,20,27,38,49,52,55,58-nonaoxo-18H,27H-5a,29-(iminocthaniminoethanimino ethaniminoethanimino[7,2]quinolinomethanoxy methano)-9,6:19,16:26,23:33,30-tetranitrilo-16H,33aH-imidazo[1',5':1,6]pyrido [3,2-m][1,11,17,24,4,7,20,27]tetrathiatetraazacyclotriacontin-1-yl]carbonyl]-2,3-didehydroalanyl-2,3-didchydro-alanine methyl ester stereoisomer), micacocidin A ((OC-6-26-A)-[(4S)-2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[2-(hydroxy-.kappa.O)-6-pentylphcnyl]-4-thiazolyl-.kappa.N3]-3-methyl-4-thiazolidinyl-.kappa.N3]-2-(hydroxy-.kappa.O)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-4-thiazolecarboxylato(2-)-.kappa.N3, .kappa.O4]-Zinc), SR-15402 ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-2-oxo-5-[(3S)-3-pyrrolidinylthio]-azeto[2,1-a]isoindole-4-carboxylic acid), ~~SUN A0026,~~ TOC 39 (1-(2-amino-2-oxoethyl)-4-[[(1E)-2-[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-cn-3-yl]ethenyl]thio]-pyridinium inner salt), carumonam ([[(Z)-[2-[[(2S,3S)-2-[[(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidinyl]amino]-1-(2-amino-4-thiazolyl)-2-oxoethylidene]amino]oxy]-acetic acid), Cefozopran (1-[[(6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxy imino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium inner salt), Cefetamet pivoxil ((6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), and T 3811 (des-F(6)-quinolone).

24. (Currently amended) The method according to claim 22, wherein said antimicrobial agent is selected from the group consisting of imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, teicoplanin, Ziracin (56-deacctyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-hexopyranosyl)flambamycin), LY333328 (oritavancin), ~~CL 331002, HMR3647~~ HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), Linezolid (N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide), Synercid (dalfopristin-quinupristin), Aztreonam (2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl] amino]-2-oxocthylidene]amino]oxy]-2-methyl-propanoic acid), and Metronidazole (2-methyl-5-nitro-1H-imidazole-1-ethanol).

25. (Currently amended) The method according to claim 17, wherein said subject is selected from the group consisting of a human ~~or~~ and an animal.

26. (Original) The method according to claim 25, wherein said subject is a human.

27. (Previously presented) The compound of claim 1 having the formula (II):



(II)

wherein R^{56} is an optionally substituted straight-chain C_8-C_{14} alkyl group.

Claims 28-29 (Canceled)

30. (Currently amended) A method of using the compound according to claim 27 to make a compound according to either of claims 1 or 2 of the formula:



31. (Previously presented) The compound according to either of claims 1 or 2 wherein said compound is selected from

Cpd #	R	R^1	R^2
1	$NHCONH(CH_2)_7CH_3$	NH_2	
2	$NHCONH(CH_2)_{11}CH_3$	NH_2	
3	$NHCONH(CH_2)_{10}CH_3$		

5			
17	$NHCONH(CH_2)_{11}CH_3$		
48	$NHCONH(CH_2)_{10}CH_3$	NH_2	
56	$NHCONH(CH_2)_7CH_3$		
57	$NHCONH(CH_2)_{10}CH_3$		
58	$NHCONH(CH_2)_{11}CH_3$		
62	$NHCONH(CH_2)_7CH_3$		
63	$NHCONH(CH_2)_{10}CH_3$		
64	$NHCONH(CH_2)_{11}CH_3$		
69	$NHCONH(CH_2)_7CH_3$		
70	$NHCONH(CH_2)_7CH_3$		
71	$NHCONH(CH_2)_7CH_3$		
75	$NHCONH(CH_2)_{10}CH_3$		

76	$NHCONH(CH_2)_7CH_3$		
77	$NHCONH(CH_2)_7CH_3$		
78	$NHCONH(CH_2)_7CH_3$		
87	$NHCONH(CH_2)_{11}CH_3$		
88	$NHCONH(CH_2)_{11}CH_3$		
89	$NHCONH(CH_2)_{11}CH_3$		
108	$NHCONH(CH_2)_{10}CH_3$		
113	$NHCONH(CH_2)_{10}CH_3$		
114	$NHCONH(CH_2)_{10}CH_3$		
117	$NHCONH(CH_2)_8CH_3$	NHBoc	
118	$NHCONH(CH_2)_8CH_3$	NH_2	
119	$NHCONH(CH_2)_9CH_3$	NHBoc	
120	$NHCONH(CH_2)_9CH_3$	NH_2	

32. (Previously presented) The compound according to claim 31 wherein said

compound is selected from

Cpd #	R	R^1	R^2
2	$NHCONH(CH_2)_{11}CH_3$	NH_2	
3	$NHCONH(CH_2)_{10}CH_3$		
48	$NHCONH(CH_2)_{10}CH_3$	NH_2	
89	$NHCONH(CH_2)_{11}CH_3$		
118	$NHCONH(CH_2)_8CH_3$	NH_2	
120	$NHCONH(CH_2)_9CH_3$	NH_2	

33. (Previously presented) The compound according claim 2, wherein R is selected from the group consisting of:

 and  ;

wherein each of R^3 and R^5 is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and whercin R^{200} is aryl.

34. (Currently amended) The compound according to claim 33, wherein R is



;

and wherein $R^{4'}$ is ~~selected from the group consisting of~~ a substituted phenyl.

35. (Previously presented) The compound according to claim 34, wherein R is



;

and wherein X^3 is chloro or trifluoromethyl.

36. (Currently amended) The method according to claim 23, wherein anti-folate agents are sulfonamides or synthetic antibacterials are selected from the group consisting of nitrofurans, methenamine mandelate and methenamine hippurate.